	Application No.	Applicant(s)
	10/820 107	VALLADEALLET AL
Notice of Allowability	10/829,107 Examiner	VALLADEAU ET AL. Art Unit
	Deday O Ourde DLD	4045
	Rodney P. Swartz, Ph.D.	1645
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 31March2005.		
2. The allowed claim(s) is/are 6-15 renumbered 1-10.		
3. The drawings filed on are accepted by the Examiner.		
4.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendn	e

Application/Control Number: 10/829,107 Page 2

Art Unit: 1645

DETAILED ACTION

Applicants' Response to Office Action, received 31March2005, is acknowledged. Claims
 1-5 have been cancelled. Claims 6 and 7 have been amended. New claims 10-15 have been added.

2. Claims 6-15 are pending and under consideration.

Rejection Withdrawn

3. The rejection of claims 6-9 under 35 U.S.C. 112, second paragraph, indefiniteness, is withdrawn in light of the amendment of the claims.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michael G. Biro, Reg. No.46,556, on 1 June 2005.

The application has been amended as follows:

In the claims:

Claim 9 (currently amended). A process for recombinantly producing the polypeptide of SEQ ID NO:4 comprising culturing the host cell of claim 8 under conditions in which the polypeptide is expressed.

Application/Control Number: 10/829,107 Page 3

Art Unit: 1645

Claim 15 (currently amended). A process for recombinantly producing a polypeptide comprising amino acids 118-144 of SEQ ID NO:4 comprising culturing the host cell of claim 14 under conditions in which the polypeptide is expressed.

Conclusion

5. Claims 6-15 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F. Smith, can be reached on (571)272-0864.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit 1645

June 1, 2005

PRIMARY EXAMINER